Ionis Pharmaceuticals Inc (NASDAQ:IONS) and Ono Pharmaceutical Co., Ltd entered into a license agreement in which Ono obtains exclusive global rights for the development and commercialization of ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

1 Day 4528 0.09% DJIA 0.01% S&P 500 0.16% Health Care/Life Sciences 0.63% ...

Image credit: Shutterstock/ Suan Taang. Japan-based Ono Pharmaceuticals has secured the global rights to sapablursen, an RNA-targeting therapy developed by Ionis Pharmaceuticals for the treatment of ...

Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) and Ono Pharmaceutical Co., Ltd (Ono), today announced that the two companies have entered into a license a ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...

Ono Pharmaceutical has claimed FDA approval for Romvimza as a treatment for tenosynovial giant cell tumour (TGCT), setting up a market tussle with Daiichi Sankyo. CSF-1R inhibitor Romvimza ...

Carlsbad’s Ionis Pharmaceuticals struck a deal worth up to $940 million with Japan-based Ono Pharmaceutical for its medicine ...

MILAN--(BUSINESS WIRE)--Sibylla Biotech announced today a drug discovery collaboration with Ono Pharmaceutical Co., Ltd. (TSE: ...